Anaplastic Thyroid Cancer
33
5
9
11
Key Insights
Highlights
Success Rate
69% trial completion
Published Results
11 trials with published results (33%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
15.2%
5 terminated out of 33 trials
68.8%
-17.8% vs benchmark
3%
1 trials in Phase 3/4
100%
11 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (33)
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Sacituzumab govitEcan in THYroid Cancers
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
European Multicenter Study on Surgical Management of Advanced Thyroid Cancer
Phase I/II Study of PDR001 in Patients With Advanced Malignancies